The deal aligns with GSK’s strategy of building a differentiated, high-value specialty medicines portfolio without significantly altering leverage or near-term free cash flow expectations.
Our credit view of this issuer reflects its low leverage and improving credit metrics, constrained by its degree of event risk related to acquisitions.
The acquisition improves the company's respiratory pipeline in the context of patent cliffs arising later in the decade. Leverage metrics are unaffected
Our credit view of this issuer reflects its low leverage and improving credit metrics, constrained by its degree of event risk related to acquisitions.